Investor Overview

Corporate Profile
Dermira is a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases.
Featured Reports
There are currently no items available.
Recent Newsmore >
DateTitle
08/08/16Dermira Reports Second Quarter 2016 Financial Results and Provides Corporate Update
Reported Topline Results for Two Late-Stage Clinical Programs Raised Approximately $136 Million in Net Proceeds from Follow-on Public Offering Updates Guidance for Topline Phase 3 CIMZIA® (certolizumab pegol) Clinical Program Results MENLO PARK, Calif., Aug. 08, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermat... 
06/13/16Dermira Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
MENLO PARK, Calif., June 13, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases, today announced that it has closed its previously announced public offering of 5,175,000 shares of its common stock, including 675,000 shares sold upon full exercise of the underwriters’ option to purchase additional shares of commo... 
06/08/16Dermira Prices $126 Million Public Offering of Common Stock
MENLO PARK, Calif., June 08, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases, today announced the pricing of its underwritten public offering of 4,500,000 shares of its common stock at a price to the public of $28.00 per share. The gross proceeds to Dermira from the offering, before deducting the underwriting... 
06/07/16Dermira Announces Proposed Public Offering of Common Stock
MENLO PARK, Calif., June 07, 2016 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to identifying, developing and commercializing innovative, differentiated therapies to improve the lives of patients with dermatologic diseases, today announced that it intends to offer shares of its common stock in an underwritten public offering. Dermira also expects to grant to the underwriters a 30-day option to purchase additional shares of its common stock in an amount... 
Stock Quotemore >
DERM (Common Stock)
Exchange :NASDAQ GS (US Dollar)
Price :$31.32
Change (%) : Stock is Down 0.53 (1.66%)
Volume :295,380
Data as of 08/25/16 4:00 p.m. ET
Minimum 20 minutes delay
Eventsmore >
There are currently no events scheduled.
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Dermira, Inc. posts new information to the site. Just enter your e-mail address and click Submit.
 

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.
Minimum 20 minutes delayed